The variation in instantaneous heart rate is most prominent in infants and younger subjects. In a preliminary study of the effects of maturation on heart rate, we compared the heart rate variations of 29 children and young adults in three groups between 5 and 24 years of age. We used spectral analysis to determine the intensity of the variations in each of the two main frequency bands in which variations occur: HF, 0.15-0.45 Hz, and LF, 0.03-0.15 Hz. Three-minute segments of continuous instantaneous heart rate were recorded for each subject in standing and supine positions. The group mean LF and HF amplitudes and the L/H ratio decreased between 5 and 10 years of age in both positions, significantly for LF and L/H in the supine position (p less than 0.05). Half of the youngest group of children had adult LF amplitude values by 5 years of age; the others had much higher levels, indicating increased low frequency variation at this age. Thus the high variation in heart rate in very young subjects is most prominent in the LF range. These preliminary results, considered with previous pharmacological studies, suggest that many children have a significant decrease in sympathetic activity between 5 and 10 years of age and possibly a slight decrease in parasympathetic activity. Spectral analysis of heart rate appears a promising technique for investigating the development of neural control of the heart.

Download full-text PDF

Source
http://dx.doi.org/10.1139/y87-320DOI Listing

Publication Analysis

Top Keywords

heart rate
24
years age
16
spectral analysis
12
instantaneous heart
8
heart
7
rate
6
years
5
age
5
heart-rate variability
4
children
4

Similar Publications

Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.

Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.

View Article and Find Full Text PDF

Background: Despite increasing awareness in general practice, heart failure with preserved ejection fraction (HFpEF) remains under-diagnosed in the community due to diagnostic difficulties. Dedicated dyspnea clinics are responsible for diagnosing HFpEF and efficient referral from primary care physicians is the key to enhance its role.

Methods: This retrospective analysis was performed to assess the effectiveness of a one-year collaborative project between our dyspnea clinic and the Maebashi Medical Association.

View Article and Find Full Text PDF

Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity including patients with different phenotypes of near normal, normal, and supernormal left ventricular (LV) function.

Objectives: To assess the value of resting LV elastance (also known as force) with transthoracic echocardiography (TTE) to identify HFpEF phenotypes.

Methods: In a prospective, observational, multicenter study, 2380 HFpEF patients were recruited from July 2016 to May 2024.

View Article and Find Full Text PDF

Clinical Outcomes after Transcatheter Aortic Valve Implantation in Nonagenarian Patients: a Retrospective Population-Based Cohort Study.

Ann Epidemiol

January 2025

IRCCS Centro Cardiologico Monzino, Department of Cardiovascular Surgery, 20138 Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20100 Milan, Italy.

Purpose: To compare the overall survival and the risk of all-cause and heart failure-specific hospitalization in nonagenarian patients hospitalized for symptomatic severe aortic stenosis (AS) who underwent transcatheter aortic valve implantation (TAVI) or conservative treatment.

Methods: Population-based retrospective cohort study based on healthcare utilization databases of the Italian region of Lombardy. The cohort included all nonagenarians hospitalized for AS between 2017 and 2021, who underwent TAVI within 90 days from first diagnosis or conservative treatment.

View Article and Find Full Text PDF

Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.

Lancet Diabetes Endocrinol

January 2025

British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:

Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.

Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!